Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders, such as status epilepticus, CDKL5 deficiency disorder, and tuberous sclerosis complex.